GlassScriptPhysician profile
Ankit R Chander
NPI 1164569083
$256.24
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.32 · 2020: $31.17 · 2021: $103 · 2022: $50.25.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $62.93 | 2021 | |
| Fidia Pharma USA INC. | $28.75 | 2019 | |
| Nevro Corp. | $21.67 | 2021 | |
| Scynexis, INC. | $19.19 | 2022 | |
| Phadia US INC. | $18.47 | 2022 | |
| Bardy Diagnostics, INC. | $17.90 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.97 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.36 | 2019 | |
| Therapeuticsmd, INC. | $14.20 | 2020 | |
| Valeritas, INC. | $13.98 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.23 | 2019 | |
| Currax Pharmaceuticals LLC | $12.59 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ankit Chander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.